[HTML] springer.com

[HTML][HTML] Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19

C Tisch, E Xourgia, A Exadaktylos, M Ziaka - Endocrine, 2024 - Springer
Objective SGLT-2i are increasingly recognized for their benefits in patients with
cardiometabolic risk factors. Additionally, emerging evidence suggests potential applications …
相关文章

Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19.

C Tisch, E Xourgia, A Exadaktylos, M Ziaka - Endocrine, 2024 - boris.unibe.ch
OBJECTIVE SGLT-2i are increasingly recognized for their benefits in patients with
cardiometabolic risk factors. Additionally, emerging evidence suggests potential applications …

Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19.

C Tisch, E Xourgia, A Exadaktylos, M Ziaka - Endocrine, 2024 - europepmc.org
Objective SGLT-2i are increasingly recognized for their benefits in patients with
cardiometabolic risk factors. Additionally, emerging evidence suggests potential applications …

Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19

C Tisch, E Xourgia, A Exadaktylos, M Ziaka - Endocrine - pubmed.ncbi.nlm.nih.gov
Objective SGLT-2i are increasingly recognized for their benefits in patients with
cardiometabolic risk factors. Additionally, emerging evidence suggests potential applications …